痰瘀双清方治疗隐匿型冠心病临床研究  

Clinical Observation on Progress of Phlegm and Blood Stasis Shuangqing Prescription in Treatment of Latent Coronary Heart Disease

作　　者：陈宝财[1] 马小允[2] 才晓茹[1] 牛占忠[1] CHEN Baocai;MA Xiaoyun;CAI Xiaoru(Acupuncture Teaching and Research Section,Department of Medicine,Cangzhou Medical College,Hebei Cangzhou 061001;不详)

机构地区：[1]沧州医学高等专科学校医学系针推教研室,河北沧州061001 [2]沧州医学高等专科学校扁鹊研究所,河北沧州061001

出　　处：《河北中医》2020年第11期1628-1632,共5页Hebei Journal of Traditional Chinese Medicine

基　　金：沧州市科技支撑计划项目(编号:162302110)。

摘　　要：目的观察痰瘀双清方治疗隐匿型冠心病的临床疗效。方法将120例隐匿型冠心病患者按照随机数字表法分为2组。对照组60例采用西药常规治疗,治疗组60例在对照组治疗基础上予痰瘀双清方治疗。2组均治疗3个月。2组治疗前后比较血脂[总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)]及血清超敏C反应蛋白(hs-CRP)水平、动态心电图[心肌缺血负荷、ST段压低阵次、持续时间、下移面积]及超声心动图[每搏输出量(SV)、每搏指数(SVI)、左室射血分数(LVEF)、心率(HR)、每分输出量(CO)、心指数(CI)]指标改善情况,并评价治疗期间用药安全性。结果治疗后2组TC、TG、LDL-C、hs-CRP均较本组治疗前降低(P<0.05),HDL-C均升高(P<0.05),且治疗后治疗组TC、TG、LDL-C、hs-CRP均低于对照组(P<0.05),HDL-C高于对照组(P<0.05)。治疗后2组心肌缺血负荷、ST段压低阵次、ST段压低持续时间、ST段下移面积均较本组治疗前降低(P<0.05),且治疗后治疗组均低于对照组(P<0.05)。治疗后治疗组SV、SVI、LVEF、CO、CI均较本组治疗前升高(P<0.05),HR降低(P<0.05),且治疗后治疗组SVI、LVEF、CO均高于对照组(P<0.05),HR低于对照组(P<0.05)。2组无不良反应发生。结论痰瘀双清方对隐匿型冠心病患者的血脂水平具有调节作用,可降低hs-CRP水平,保护血管,改善心肌缺血,提升心脏功能,且用药安全,值得临床推广。Objective To observe the effect of Tanyu Shuangqing Prescription on blood lipid,hs-CRP,Dynamic ECG and echocardiography in the treatment of latent coronary heart disease. Methods A total of 120 patients with latent coronary heart disease were randomly divided into two groups. 60 cases in the control group were treated with conventional western medicine,and 60 cases in the treatment group were treated with phlegm and blood stasis Shuangqing prescription on the basis of the control group. Both groups were treated for 3 months. The levels of blood lipids [total cholesterol( TC),triglyceride( TG),high density lipoprotein cholesterol( HDL-C),low density lipoprotein cholesterol( LDL-C) ]and serum high-sensitivity C-reactive protein( hs-CRP),the improvement of dynamic electrocardiogram [myocardial ischemia load,ST segment depression array,duration,downward area ]and echocardiography[stroke volume( SV),stroke index( SVI),left ventricular ejection fraction( LVEF),heart rate( HR),per minute output( CO),heart index( CI) ]were compared between the two groups before and after treatment,and the safety of medication was evaluated. Results After treatment,TC,TG,LDL-C and hs-CRP in the two groups were lower than those before treatment( P < 0. 05),and HDL-C was increased( P < 0. 05). After treatment,TC,TG,LDL-C and hs-CRP in the treatment group were lower than those in the control group( P <0. 05),and HDL-C was higher than that in the control group. After treatment,the myocardial ischemia load,ST segment depression time,ST segment depression duration and ST segment depression area in the two groups were lower than those before treatment( P < 0. 05),and those in the treatment group were lower than the control group( P <0. 05). After treatment,SV,SVI,LVEF,CO and CI in the treatment group were higher than those before treatment( P < 0. 05),and HR was lower( P < 0. 05). After treatment,SVI,LVEF and CO in the treatment group were higher than those in the control group( P < 0. 05),and HR was lower than that in the control group( P < 0.

关 键 词：冠心病 中药疗法 

分 类 号：R541.405.31[医药卫生—心血管疾病]